Zhengye Biotechnology Holding (ZYBT) Non-Current Deferred Tax Liability (2025)
Zhengye Biotechnology Holding (ZYBT) posted quarterly Non-Current Deferred Tax Liability of $14663.2 for Q4 2025.
Zhengye Biotechnology Holding (ZYBT) Non-Current Deferred Tax Liability (2025) Analysis & Trends
Zhengye Biotechnology Holding (ZYBT) has reported Non-Current Deferred Tax Liability for 1 consecutive years, with $14663.2 the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Deferred Tax Liability changed N/A year-over-year to $14663.2; the TTM figure through Dec 2025 stood at $14663.2 (changed N/A YoY), while the FY2025 annual figure was $15000.0, changed N/A from the prior year.
- Non-Current Deferred Tax Liability steadied at $14663.2 in Q4 2025 per ZYBT's latest filing.
- Across five years, Non-Current Deferred Tax Liability topped out at $14663.2 in Q4 2025 and bottomed at $14663.2 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - |
| 10 | Zhengye Biotechnology Holding | 88.82 Mn | 81.50 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 14,663.23 |
| Dec 31, 2025 | 14,663.23 |